- Nivolumab - Immunotherapy Cancer Treatment

nivolumab.coWebsite Profile

Title: Nivolumab - Immunotherapy Cancer Treatment
Description:The anti cancer drug Nivolumab is showing promise in the treatment of melanoma and may be effective on lung and renal cancers. is ranked 25408406 in the world (amongst the 40 million domains). A low-numbered rank means that this website gets lots of visitors. This site is relatively popular among users in the united states. It gets 50% of its traffic from the united states .This site is estimated to be worth $2,503. This site has a low Pagerank(0/10). It has 1 backlinks. has 43% seo score. Information

Website /
Website IP Address:
Domain DNS, ranks

Alexa Rank:0
EveryoneDomain Rank:0
Google Page Rank:0/10 (Google Pagerank Has Been Closed) Traffic & Earnings

Purchase/Sale Value:$0
Daily Revenue:$0
Monthly Revenue:$0
Yearly Revenue:$$0
Daily Unique Visitors:0
Monthly Unique Visitors:0
Yearly Unique Visitors:0 WebSite Httpheader

StatusCode 200
Connection Keep-Alive
Content-Type text/html
Server Apache
Date Tue, 18 Sep 2018 12:36:30 GMT WebSite Httpheader

Keyword Count Percentage Similar Website

Domain WebSite Title News on Cancer Treatment and Immunotherapy in China Orbis Health Solutions - Immunotherapy Treatment for Cancer and Beyond Perseus PCI | Cancer Treatment Vaccine | Immunotherapy Cancer Immunotherapy, Instituto de Medicina Regenerativa | Stem Cell Treatment Immunotherapy for Cancer | Cancer Immunotherapy | Alternative Cancer Clinics Accelerating Cancer Immunotherapy | Accelerating Cancer Immunotherapy 2017 Dendritic Cell Immunotherapy, Cancer Dendritic Cell, Cancer Treatment India - news: DENVAX-O ( for?... Society for Immunotherapy of Cancer (SITC) Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Trials Network Accelerating Cancer Immunotherapy Research CANCER IMMUNOTHERAPY & IMMUNOMONITORING Loncar Cancer Immunotherapy Index Immunotherapy Foundation - Fighting Cancer ITOC - Immunotherapy of Cancer ConferenceITOC Parker Institute for Cancer Immunotherapy Homepage | Curing Cancer With Immunotherapy Cancer Immunotherapy Resources | The Answer to Cancer Alexa Rank History Chart aleax Html To Plain Text

Nivolumab - Immunotherapy Cancer Treatment Nivolumab Cancer Treatment Drug A revolutionary cancer treatment? Higher Survival Rates Bristol Myer's new cancer treatment drug Nivolumab (pronounced NYE-vol-U-Mab) is an immunotherapy that is combined with other drugs to treat melanoma, but indications are that it may also be effective for other cancers involving the lungs and kidneys. In the investment world, analysts believe that in the next 5 years that the stock for Bristol Myers Squib could have a valuation increase greater than 25% thanks in part to the revenue per patient that this drug would create. (Note that this site does not give investment or medical advice, and the analyst who makes this claim is Andrew Baum of Citigroup.) The drug could be approved in 2014. Immunotherapies themselves may represent a brand new wave in the treatment of cancer and revolutionize survival rates and expected outcomes. Analysts indicate that these therapies could add upwards of 40 billion dollars to the pharmaceutical industry. The description for nivolumab indicates that it is a human igG4 antibody blocking the programmed cell death-1 receptor. Cancer Treatment Industry Growing While it would seem that making money from the treatment of a deadly disease should not be a basis for profitability, the fact of the matter is that many lifesaving treatments are driven by the profit motive. Furthermore, the billions of dollars made on a new cancer treatment would offset the monies "lost" to hospitalization, higher insurance premiums, and even funeral expenses for those people who would have died. The earning value of the people who now get to live and contribute to the economy also can't be counted. As any survivor of a cancer victim also knows, the loss of a loved one cannot be measured in dollars, so a treatment that may prevent suffering and death (after chemotherapy, radiation, and surgery) would be worth much more than mere dollars. Availability of Nivolumab and Use Nivolumab is typically combined with Yervoy (ipilimumab) and has been shown to lead to deep tumor regression in a third of patients who have advanced melanoma. The response is shown to be quicker when the combination is used versus a single drug In data presented in 2013 at the American Society of Clinical Oncology, the information about this combination approach involving Nivolumab was released to the public. Yervoy has already been approved by the FDA for the treatment of metastatic melanoma and other research including nivolumab has already shown promising response rates. In scientific terms, these drug are antibodies which keep T cells from fully activating, and block PD-1 and CTLA-4 braking pathways. This apparently result in immune activation. The results were seen in patients with nonresectable stage 3 and 4 metastatic melanoma. The course of this cancer treatment in one test was four doses of ipilimumab and nivolumab, every 3 weeks, then nivolumab exclusively for 3 weeks and a combination treatment every three months at week 24. As much as sixty five percent o patients had their melanoma controlled and most of this group continued to respond as of the date of the study's release. For some of the more scientific information on the drug itself, it has a molecular formula of c6362-H9862-N1712-O1995-S42. The sponsor of the drug is Bristol Myers Squbb and it falls under the code designation of MDX-1106 and BMS-936558 with a CAS Registry Number of 946414-94-4. Main menu Home Immunotherapy Melanoma Privacy Policy Resources Wikipedia Nonproprietary Name Statement Friends NIH Copyright ? 2013 | | Design by Whois

Domain ID: D44867915-CO
Sponsoring Registrar: GODADDY.COM, INC.
Sponsoring Registrar IANA ID: 146
Registrar URL (registration services):
Domain Status: clientDeleteProhibited
Domain Status: clientRenewProhibited
Domain Status: clientTransferProhibited
Domain Status: clientUpdateProhibited
Registrant ID: CR143813756
Registrant Name: Patrick Hare
Registrant Organization: Incognito Media Corporation
Registrant Address1: 17014 N 36th Ln
Registrant City: Glendale
Registrant State/Province: Arizona
Registrant Postal Code: 85308
Registrant Country: United States
Registrant Country Code: US
Registrant Phone Number: +1.6029938200
Registrant Email:
Administrative Contact ID: CR143813758
Administrative Contact Name: Patrick Hare
Administrative Contact Organization: Incognito Media Corporation
Administrative Contact Address1: 17014 N 36th Ln
Administrative Contact City: Glendale
Administrative Contact State/Province: Arizona
Administrative Contact Postal Code: 85308
Administrative Contact Country: United States
Administrative Contact Country Code: US
Administrative Contact Phone Number: +1.6029938200
Administrative Contact Email:
Billing Contact ID: CR143813759
Billing Contact Name: Patrick Hare
Billing Contact Organization: Incognito Media Corporation
Billing Contact Address1: 17014 N 36th Ln
Billing Contact City: Glendale
Billing Contact State/Province: Arizona
Billing Contact Postal Code: 85308
Billing Contact Country: United States
Billing Contact Country Code: US
Billing Contact Phone Number: +1.6029938200
Billing Contact Email:
Technical Contact ID: CR143813757
Technical Contact Name: Patrick Hare
Technical Contact Organization: Incognito Media Corporation
Technical Contact Address1: 17014 N 36th Ln
Technical Contact City: Glendale
Technical Contact State/Province: Arizona
Technical Contact Postal Code: 85308
Technical Contact Country: United States
Technical Contact Country Code: US
Technical Contact Phone Number: +1.6029938200
Technical Contact Email:
Created by Registrar: GODADDY.COM, INC.
Last Updated by Registrar: GODADDY.COM, INC.
Domain Registration Date: Wed May 22 22:19:53 GMT 2013
Domain Expiration Date: Mon May 21 23:59:59 GMT 2018
Domain Last Updated Date: Sun Apr 30 17:03:56 GMT 2017
DNSSEC: false
>>>> Whois database was last updated on: Tue May 16 10:47:08 GMT 2017 <<<.

The data contained in, LLC's WhoIs database,
while believed by the company to be reliable, is provided "as is"
with no guarantee or warranties regarding its accuracy. This
information is provided for the sole purpose of assisting you
in obtaining information about domain name registration records.
Any use of this data for any other purpose is expressly forbidden without the prior written
permission of, LLC.By submitting an inquiry,
you agree to these terms of usage and limitations of warranty.In particular,
you agree not to use this data to allow, enable, or otherwise make possible,
dissemination or collection of this data, in part or in its entirety, for any
purpose, such as the transmission of unsolicited advertising and
and solicitations of any kind, including spam.You further agree
not to use this data to enable high volume, automated or robotic electronic
processes designed to collect or compile this data for any purpose,
including mining this data for your own personal or commercial purposes.

Please note: the registrant of the domain name is specified
in the "registrant" section.In most cases,, LLC
is not the registrant of domain names listed in this database.";

For more information on Whois status codes, please visit